Imagine your physician walks into the exam room, recommends a prescription medication, and casually mentions she’s being paid by the company that makes the drug to say so. You’d probably have questions. You might even find a new doctor.
Now imagine that same scenario playing out on Instagram, TikTok, or YouTube — except the advice is coming from a celebrity “influencer” who’s very familiar to you, who has an emotional backstory, and a financial arrangement buried somewhere in a sea of hashtags. Millions of people encounter exactly this situation every day, and most of them have no idea it’s happening.
A newly published review article in a medical journal reveals a growing and underregulated public health problem: the pharmaceutical industry’s aggressive courtship of social media influencers to market prescription drugs directly to consumers. The findings are not comforting.
THE ‘WOO-WOO’ PHILOSOPHY OF TRUMP’S SURGEON GENERAL PICK
The researchers analyzed a decade’s peer-reviewed literature on influencer-driven prescription drug promotion and found three alarming patterns. First, influencers routinely spread misinformation about the safety and efficacy of drugs they’re paid to endorse — not out of malice, necessarily, but because they simply lack the medical expertise to know better.
Second, although the Food and Drug Administration requires that prescription drug ads be truthful, balanced, and not misleading, and must disclose risks alongside benefits, regulatory oversight of this practice is pathetically weak. Enforcement actions consist largely of strongly worded letters that carry all the deterrent force of a politely disappointed email.
Third — and most insidiously — the personal, emotional storytelling at the heart of influencer culture makes audiences uniquely vulnerable to persuasion, precisely because it bypasses the critical thinking (and the usual litany of possible side effects) that more obvious drug advertising tends to trigger.
The Khloe Kardashian case is instructive. Kardashian, who boasts roughly 300 million social media followers, promoted the migraine drug rimegepant sulfate (brand name Nurtec ODT) with claims the FDA later determined were false and misleading. The agency’s response? A pathetic “untitled letter” to the drug’s manufacturer. Not a fine. Not a suspension. Not even a warning letter; merely a request to shape up.
The result is that people are often unaware of the proper use of drugs, the likelihood of benefits, and the possible side effects.
This is not a niche problem confined to celebrity endorsements. The journal article documents a sprawling ecosystem of lesser “micro-influencers” — wellness personalities, fitness coaches, and the like — who maintain quiet financial relationships with pharmaceutical companies while presenting themselves as ordinary people sharing authentic experiences. These relationships are frequently undisclosed, often technically in violation of existing Federal Trade Commission guidelines that are almost never enforced.
The lure of such misleading advertising is worth understanding. Social media users develop what psychologists call “para-social bonds” with influencers they follow — a one-sided sense of intimacy and trust that mimics real friendship. When someone you feel you know and admire describes how a medication transformed her life, you don’t process that the way you process a television commercial with singing, dancing actors. The emotional resonance is higher, the skepticism is lower, the required warnings about side effects are absent, and the persuasive effect is correspondingly stronger. Experimental studies have shown that audiences frequently struggle to distinguish between a genuine personal testimonial and paid promotional content, even when disclosure language is technically present.
Congress and federal regulators have not kept pace with the trend. The FTC’s influencer disclosure guidelines are outdated, the FDA’s enforcement posture toward social media is inconsistent, and platforms including Instagram and TikTok have largely been left to police themselves — which is to say, they largely haven’t.
What should be done? The researchers offer a practical framework, and it deserves bipartisan support. Disclosure requirements need to be standardized, prominent, and actually enforced — not buried in hashtag soup or at the bottom of a wall of text. Platforms should be held accountable for pharmaceutical content that violates disclosure standards. And investment in digital health literacy — teaching Americans to recognize promotional content when it’s embedded in personal narratives — is long overdue.
RFK JR. AND DR. OZ SAY HOSPITALS WILL LOSE FUNDING IF THEY SERVE UNHEALTHY FOOD
There is a tendency in Washington to treat social media regulation as either a First Amendment minefield or a culture-war proxy battle. Prescription drug promotion by influencers is neither. It is a consumer protection issue, a public health issue, and, given the opioid epidemic’s brutal lessons about the consequences of pharmaceutical overprescribing, a matter of genuine urgency. I am the first to agree that pharmaceuticals often perform miracles for patients, but there are reasons they are regulated.
The pharmaceutical industry is extraordinarily adept at finding new channels to reach patients before physicians do. Social media influencers are simply the latest and most effective vector. It’s past time for the rules to catch up.
Henry I. Miller, a physician and molecular biologist, is the Glenn Swogger Distinguished Scholar at the Science Literacy Project. He was the founding director of the Food and Drug Administration’s Office of Biotechnology. Find Henry on his website: henrymillermd.org.
